Wells Fargo assumed coverage of Gracell with an Overweight rating and $7 price target, with no changes made to rating or target.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on GRCL:
- Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
- Gracell sees cash runway to the end of 2024
- Gracell reports Q4 EPS (6c), consensus (13c)
- Gracell Biotechnologies Reports Fourth Quarter and Full Year 2022 Unaudited Financial Results, and Provides Corporate Update
- Gracell management to meet virtually with Jefferies